VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2015 | Overview of a promising new study of venetoclax in patients with CLL

Jacqueline Barrientos, MD, from the North Shore-Long Island Jewish Health System in New York, discusses a promising new study of the anti-apopotopic (Bcl-2 inhibitor) venetoclax in patients with CLL. Early data suggest that this may achieve minimum residual disease (MRD) negativity with a low risk of side effects.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter